Summary
Unselected intramuscular (IM) and intravenous (IV) immunoglobulins, as well as virus-specific hyperimmune globulins, occupy important roles as immunotherapy for viral infections.
Standard IM immunoglobulins may be utilised in selected, susceptible patients for the prevention of hepatitis A and measles. Hyperimmune globulins to varicella zoster virus (VZV), hepatitis B virus and rabies have established indications for use as post-exposure prophylaxis. Cytomegalovirus (CMV) hyperimmune globulin has an indication for the prevention of primary CMV-associated disease in kidney transplantation and has been shown to decrease severe CMV-associated disease in liver transplantation. More recently, respiratory syncytial virus (RSV) hyperimmune globulin has been developed and is being utilised to prevent RSV disease in high risk infants and children during months of maximum risk for RSV infection.
Unselected IV immunoglobulins (IVIg) have proven beneficial in preventing CMV-associated disease and graft-versus-host-disease in allogeneic bone marrow transplant recipients. In addition, IVIg plus ganciclovir is effective therapy for established CMV disease in both bone marrow and solid organ transplantation. IVIg for chronic anaemia associated with parvovirus B19 infection is gaining acceptance, as is the use of IVIg and intraventricular immunoglobulin for chronic meningoencephalitis associated with agammaglobulinaemia.
Immunotherapy for the prevention or treatment of several other viral infections has been explored, but without clear conclusions. The use of human immunodeficiency virus (HIV) hyperimmune globulins in HIV-infected patients has yielded inconsistent results and the role of such therapy in the era of highly active antiretroviral therapy is uncertain. Oral immunoglobulins appear successful for rotaviral infections, but their exact use requires further clarification. Other immunotherapeutic modalities, such as monoclonal antibodies against CMV, RSV and HIV, have been developed but these agents have not undergone extensive clinical evaluation.
Article PDF
Similar content being viewed by others
References
McKhann CF, Greene AA, Coady H. Factors influencing the effectiveness of placental extract in the prevention and modification of measles. J Pediatr 1935; 6: 603–14
Cohn EF, Oncley JL, Strong LE, et al. Chemical, clinical, and immunological studies on the products of human plasma fractionation. I. The characterization of protein fractions of human plasma. J Clin Invest 1944; 23: 417–32
Ordman CW, Jenning CG, Janeway CA. Chemical, clinical, and immunological studies on the products of human plasma fractionation. XII. The use of concentrated normal human serum gammaglobulin (human immune serum globulin) in the prevention and attenuation of measles. J Clin Invest 1944; 23: 541–9
Kempe CH, Berge TO, England B. Hyperimmune vaccinal gamma globulin. Source, evaluation, and use in prophylaxis and therapy. Pediatrics 1956; 18: 177–88
Barandun S, Isliker H. Development of immunoglobulin preparations for intravenous use. Vox Sang 1986; 51: 157–60
Reynolds JEF, editor. Vaccines, immunoglobulins and antisera. In: Martindale: the extra pharmacopoeia. London: Royal Pharmaceutical Society of Great Britain, 1996: 1609–50
Siber GR, Snydman DR. Use of immune globulins in the prevention and treatment of infections. Curr Clin Top Infect Dis 1992; 12: 208–56
Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 1994; 97(1 Suppl.): 79–83
Yap PL. The viral safety of intravenous immune globulin. Clin Exp Immunol 1996; 104(1 Suppl.): 35–42
Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336(3): 196–204
Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996; 45(RR-15): 1–30
Committee on Infectious Diseases. Prevention of hepatitis A infections: guidelines for use of hepatitis A vaccine and immune globulin. Pediatrics 1996; 98(6): 1207–15
Centers for Disease Control and Prevention. Hepatitis B virus. A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1991; 40(RR-13): 1–25
Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842–7
Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327–33
Centers for Disease Control and Prevention. Rabies Prevention — United States, 1991: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1991; 40(RR-3): 1–19
Wilde H, Chomchey P, Punyaratabandhu P, et al. Purified equine rabies immune globulin: a safe and affordable alternative to human rabies immune globulin. Bull WHO 1989; 67: 731–6
Wilde H, Chutivongse S, Hemachudha T. Rabies and its prevention. Med J Aust 1994; 160: 83–7
Fishbein DB, Robinson LE. Rabies. N Engl J Med 1993; 329: 1632–8
WHO. Expert Committee on Rabies. World Health Organ Tech Rep Ser 1992; 824: 1–84
Winston DJ, Pollard RB, Ho WG, et al. Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann Intern Med 1982; 97: 11–8
Meyers JD, Leszczynski J, Zaia JA, et al. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med 1983; 98: 442–6
Condie RM, O’Reilly RJ. Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients. Am J Med 1984; 76(3A): 134–41
Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986; 314: 1006–10
Ringden O, Pihlstedt P, Volin L, et al. Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant 1987; 2: 299–305
Winston DJ, Ho WG, Lin CH, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987; 106: 12–8
Sullivan KM, Kopecky KJ, Jacom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323: 705–12
Bowden RA, Fisher LD, Rogers K, et al. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis 1991; 164: 483–7
Bass EB, Powe NR, Goodman SN, et al. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 1993; 12: 273–82
Messori A, Rampazzo R, Scroccaro G, et al. Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 1994; 13: 163–7
Glowacki LS, Smaill FM. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients — a meta-analysis. Clin Transpl 1994; 8: 10–8
Wittes JT, Kelly A, Plante KM. Meta-analysis of CMVIG studies for the prevention and treatment of CMV infection in transplant patients. Transplant Proc 1996; 28(6): 17–24
Schmidt GM, Morak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic marrow transplants. N Engl J Med 1991; 324: 1005–11
Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601–7
Guglielmo BJ, Wong-Beringer A, Linker CA. Immune globulin therapy in allogeneic bone marrow transplant: a critical review. Bone Marrow Transplant 1994; 13: 499–510
Sullivan KM. Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease. Clin Exp Immunol 1996; 104(1 Suppl.): 43–8
Wolff SN, Fay JW, Herzig RH, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. Ann Intern Med 1993; 118: 937–42
Gregor B, Vallbracht A, Kurth J, et al. The clinical value of CMV prophylaxis by CMV hyperimmune serum in the kidney transplant patient. Transplant Proc 1986; 18: 1387–9
Fassbinder W, Ernst W, Hanke P, et al. Cytomegalovirus infections after renal transplantation: effect of prophylactic hyperimmunoglobulin. Transplant Proc 1986; 13: 1393–6
Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987; 317: 1049–54
Kasiske BL, Heim-Duthoy KL, Tortorice KL, et al. Polyvalent immune globulin and cytomegalovirus infection after renal transplantation. Arch Intern Med 1989; 149: 2733–6
Conti DJ, Freed BM, Gruber SA, et al. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. Arch Surg 1994; 129: 443–7
Snydman DR, Werner BG, Tilney NL, et al. Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials. Transplant Proc 1991; 23: 1357–60
Werner BG, Snydman DR, Freeman R, et al. Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: analysis of usage under treatment IND status. The treatment IND study group. Transplant Proc 1993; 25: 1441–3
Nightingale SL. From the Food and Drug Administration. JAMA 1990; 264: 168
Rubin RH. Preemptive therapy in immunocompromised hosts. N Engl J Med 1991; 324: 1057–9
Metselaar HJ, Rothbarth PH, Brouwer RML, et al. Prevention of cytomegalovirus-related death by passive immunization. Transplantation 1989; 48: 264–6
Steinmuller DR, Novick AC, Streem SB, et al. Intravenous immunoglobulin infusions for the prophylaxis of secondary cytomegalovirus infection. Transplantation 1990; 49: 68–70
Cofer JB, Morris CA, Sutker WL, et al. A randomized double-blind study of the effect of prophylactic immune globulin on the incidence and severity of CMV infection in the liver transplant recipient. Transplant Proc 1991; 23: 1525–7
Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993; 119: 984–91
Snydman DR, Werner BG, Dougherty NN, et al. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Transplant Proc 1994; 26(1 Suppl.): 23–7
Saliba F, Arulnaden JL, Gugenheim J, et al. CMV hyperimmune globulin prophylaxis after liver transplantation: a prospective randomized controlled study. Transplant Proc 1989; 21: 2260–2
Stratta RJ, Shaeter MS, Cushing KA, et al. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg 1992; 127: 55–64
Falagas ME, Snydman DR, Ruthazer R, et al. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. Clin Transplant 1997; 11: 432–7
Boland GJ, Ververs C, Hene RJ, et al. Early detection of primary cytomegalovirus infection after heart and kidney transplantation and the influence of hyperimmune globulin prophylaxis. Transpl Int 1993; 6: 34–8
Bailey TC, Ettinger NA, Storch GA, et al. Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. Am J Med 1993; 95: 273–8
Dunn DL, Gillingham KJ, Kramer MA, et al. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation 1994; 57: 876–84
Snydman DR. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients — a metaanalysis. Clin Transplant 1995; 9: 490–1
Nicol DL, MacDonald AS, Belitsky P, et al. Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients. Transplantation 1993; 55: 841–6
Stratta RJ, Taylor RJ, Bynon JS, et al. Viral prophylaxis in combined pancreas-kidney transplant recipients. Transplantation 1994; 57: 506–12
Reed EC, Bowden RA, Dandliker PS, et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988; 109: 783–8
Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988; 109: 777–82
George MJ, Snydman DR, Werner BG, et al. Use of ganciclovir plus cytomegalovirus immune globulin to treat CMV pneumonia in orthotopic liver transplant recipients. Transplant Proc 1993; 25: 22–4
Martin M, Snydman DR, Rubin RH, et al. Question-and-answer session. High-risk transplantation. Transplant Proc 1994; 26: 31–2
Kumar PN, Palestine A, Timpone JG, et al. A prospective, randomized pilot trial of intravenous immune globulin as adjuvant therapy to ganciclovir for the treatment of CMV retinitis in patients with AIDS [abstract]. Third Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28–Feb 1; Washington, DC: 82
Paar DP, Pollard RB. Immunotherapy of CMV infections. Adv Exp Med Biol 1996; 394: 145–51
McCarthy M. CMV retinitis monoclonal antibody trial halted. Lancet 1996; 348: 603
Centers for Disease Control. Varicella-zoster immune globulin for the prevention of chickenpox. Recommendations of the immunization practices advisory committee. Ann Intern Med 1984; 100: 859–65
Zaia JA, Levin MJ, Preblud SR, et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 1983; 147: 737–43
Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996; 45(RR-11): 1–36
Paryani SG, Arvin AM, Koropchak CM, et al. Comparison of varicella-zoster antibody titers in patients given intravenous immune serum globulin or varicella-zoster immune globulin. J Pediatr 1984; 105(2): 200–5
Srugo I, Israele V, Wittek AE, et al. Clinical manifestations of varicella-zoster virus infection in human immunodeficiency virus-infected children. Am J Dis Child 1993; 147: 742–5
Stevens DA, Merigan TC. Zoster immune globulin prophylaxis of disseminated zoster in compromised hosts. A randomized trial. Arch Intern Med 1980; 140: 52–4
Chen RL, Lin KH, Lin DT, et al. Immunomodulation treatment of childhood virus-associated haemophagocytic lymphohistiocytosis. Br J Haematol 1995; 89: 282–90
Oettle H, Wilborn F, Schmidt CA, et al. Treatment with ganciclovir and Ig for acute Epstein-Barr virus infection after allogeneic bone marrow transplantation. Blood 1993; 82: 2257–62
Basgoz N, Preiksaitis JK. Post-transplant lymphoproliferative disorder. Infect Dis Clin North Am 1995; 9: 901–23
Bar RS, DeLor CJ, Clausen KP, et al. Fatal infectious mononucleosis in a family. N Engl J Med 1974; 290: 363–7
Purtilo DT, Sakamoto K, Barnabei V, et al. Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLPS): update on studies of the registry. Am J Med 1982; 73: 49–56
Sullivan JL, Byron KS, Brewster FE, et al. X-linked lymphoproliferative syndrome. Natural history of the immunodeficiency. J Clin Invest 1983; 71: 1765–78
Taguchi Y, Purtilo DT, Okano M. The effect of intravenous immunoglobulin and interferon-alpha on Epstein-Barr virus-induced lymphoproliferative disorder in a liver transplant recipient. Transplantation 1994; 57: 1813–5
Delone P, Corkill J, Jordan M, et al. Successful treatment of Epstein-Barr virus infection with ganciclovir and cytomegalovirus hyperimmune globulin following kidney transplantation. Transplant Proc 1995; 27: 58–9
Lamprecht CL, Krause HE, Mufson MA. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis 1976; 134: 211–7
Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89: 422–34
Meissner HC, Fulton DR, Groothuis JR, et al. Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob Agents Chemother 1993; 37: 1655–8
Siber GR, Leszczynski J, Pena-Cruz V, et al. Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J Infect Dis 1992; 165: 456–63
Groothuis JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993; 329: 1524–30
Groothuis JR, Simoes EAF, Hemming VG, et al. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Pediatrics 1995; 95: 463–7
Simoes EAF, Groothuis JR, Tristram DA, et al. Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high-risk children. J Pediatr 1996; 129: 214–9
The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatr 1997; 99: 93–9
Meissner HC, Welliver RC, Chartrand SA, et al. Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. Pediatr Infect Dis J 1996; 15: 1059–68
Nightingale SL. From the Food and Drug Administration. JAMA 1996; 275: 902
Hemming VG, Rodriguez W, Kim HW, et al. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob Agents Chemother 1987; 31: 1882–6
Rodriguez WJ, Gruber WC, Welliver RC, et al. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections. Pediatr 1997; 99: 454–61
Whimbey E, Champlin RE, Englund JA, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995; 16: 393–9
Hemming VG, Prince GA, Groothuis JR, et al. ai]Hyperimmune globulins_in prevention and treatment of respiratory syncytial virus infections. Clin Microbiol Rev 1995; 8: 22–33
Rimensberger PC, Burek-Kozlowska A, Morell A, et al. Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants. Pediatr Infect Dis J 1996; 15: 209–16
Taylor G, Porter T, Dillon S, et al. Anti-respiratory syncytial virus monoclonal antibodies show promise in the treatment and prophylaxis of viral disease. Biochem Soc Trans 1995; 23: 1063–7
Meissner C, Groothuis J, Rodriguez W, et al. Safety and pharmacokinetics of an intramuscular monoclonal antibody to RSV (SB209763) in infants and children at risk for severe RSV disease [abstract H-88]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto: American Society for Microbiology, 1997: 229
Saez-Llorens X, Castano E, Sanchez P, et al. Phase I/II, open-label, multi-dose, escalation trial of a humanized respiratory syncytial virus (RSV) monoclonal antibody (MEDI-493) administered intramuscularly (IM) in high risk children [abstract H-89]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto: American Society for Microbiology, 1997: 229
Abzug MJ, Keyserling HL, Lee ML, et al. Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. Clin Infect Dis 1995; 20: 1201–6
Abzug MJ, Levin MJ, Rotbart HA. Profile of enterovirus disease in the first two weeks of life. Pediatr Infect Dis J 1993; 12: 820–4
Nagington J, Walker J, Gandy G, et al. Use of normal immunoglobulin in an echovirus 11 outbreak in a special-care baby unit. Lancet 1983; 2: 443–6
Carolane DJ, Long AM, McKeever PA, et al. Prevention of spread of echovirus 6 in a special care baby unit. Arch Dis Child 1985; 60: 674–6
Kinney JS, McCray E, Kaplan JE, et al. Risk factors associated with echovirus 11′ infection in a hospital nursery. Pediatr Infect Dis J 1986; 5: 192–7
Johnston JM, Overall JC. Intravenous immunoglobulin in disseminated neonatal echovirus 11 infection. Pediatr Infect Dis J 1989; 8: 254–6
Valduss D, Murray DL, Karna P, et al. Use of intravenous immunoglobulin in twin neonates with disseminated coxsackie Bin1 infection. Clin Pediatr 1993: 561-3
McKinney RE, Katz SL, Wilfert CM. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis 1989; 9: 334–56
Misbah SA, Spickett GP, Ryba PCJ, et al. Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review. J Clin Immunol 1992; 12: 266–70
Dwyer JM, Erlendsson K. Intraventricular gamma-globulin for the management of enterovirus encephalitis. Pediatr Infect Dis J 1988; 7: S30–3
Kurtzman G, Frickhofen N, Kimball J, et al. Pure red-cell aplasia of 10 years’ duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989; 321: 519–23
Tang MLK, Kemp AS, Moaven LD. Parvovirus B19-associated red blood cell aplasia in combined immunodeficiency with normal immunoglobulins. Pediatr Infect Dis J 1994; 13: 539–42
Kurtzman GJ, Meyers P, Cohen Bernard, et al. Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet 1988; 2: 1159–62
Gottlieb F, Deutsch J. Red cell aplasia responsive to immunoglobulin therapy as initial manifestation of human immunodeficiency virus infection. Am J Med 1992; 92: 331–3
Mitchell SA, Welch JM, Weston-Smith S, et al. Parvovirus infection and anaemia in a patient with AIDS: case report. Genitourin Med 1990; 66: 95–6
Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 1990; 113: 926–33
Kurtzman GJ, Cohen BJ, Field AM, et al. Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest 1989; 84: 1114–23
Takahashi M, Koike T, Moriyama Y, et al. Neutralizing activity of immunoglobulin preparation against erythropoietic suppression of human parvovirus [letter]. Am J Hematol 1991; 37: 68
Schwarz TF, Roggendorf M, Hottentrager B, et al. Immunoglobulins in the prophylaxis of parvovirus B19 infection. J Infect Dis 1990; 162: 1214
Young NS. Parvovirus infection and its treatment. Clin Exp Immunol 1996; 104(1 Suppl.): 26–30
Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. MMWR Morb Mortal Wkly Rep 1993; 42(RR-5): 1–18
Ross LA, Kim KS, Mason WH, et al. Successful treatment of disseminated measles in a patient with acquired immunodeficiency syndrome: consideration of antiviral and passive immunotherapy. Am J Med 1990; 88: 313–4
Stogner SW, King JW, Black-Payne C, et al. Ribavirin and intravenous immune globulin therapy for measles pneumonia in HIV infection. South Med J 1993; 86: 1415–8
Centers for Disease Control and Prevention. Mumps prevention. MMWR Morb Mortal Wkly Rep 1989; 38: 388–92, 397-400
Centers for Disease Control and Prevention. Rubella prevention: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1990; 39(RR-15): 1–18
Karpas A, Bevan PC, Gillson W, et al. Lytic infection by British AIDS virus and development of rapid cell test for antiviral antibodies. Lancet 1985; 2: 695–6
Jacobson JM, Colman N, Ostrow NA, et al. Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J Infect Dis 1993; 168: 298–305
Levy J, Vouvan T, Lee ML, et al. Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: results of a 12-month multicenter double-blind controlled trial. Blood 1994; 84: 2130–5
Vittecoq D, Chevret S, Morand-Joubert L, et al. Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. Proc Natl Acad Sci USA 1995; 92: 1195–9
Cummins LM, Weinhold KJ, Matthews TJ, et al. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors. Blood 1991; 77: 1111–7
Stiehm ER, Mofenson L, Zolla-Pazner S, et al. Meeting report: summary of the workshop on passive immunotherapy in the prevention and treatment of HIV infection. Clin Immunol Immunopathol 1995; 75: 84–93
Collier AC, Coombs RW, Katzenstein D, et al. Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 1995; 10: 150–6
Seina Consensus Workshop II. Strategies for prevention of perinatal transmission of HIV infection. J Acquir Immune Defic Syndr 1995; 8: 161–75
Connor EM, McSherry G. Immune-based interventions in perinatal human immunodeficiency virus infection. Pediatr Infect Dis J 1994: 13: 440–8
National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991; 325: 73–80
Spector SA, Gelber RD, McGrath N, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. N Engl J Med 1994; 331: 1181–7
Working Group on Antiretroviral Therapy: National Pediatric HIV Resource Center. Antiretroviral therapy and medial management of the human immunodeficiency virus-infected child. Pediatr Infect Dis J 1993; 12: 513–22
Kiehl MG, Stoll R, Broder M, et al. A controlled trial of intravenous immune globulin for the prevention of serious infections in adults with advanced human immunodeficiency virus infection. Arch Intern Med 1996; 156: 2545–50
Yap PL. Does intravenous immune globulin have a role in HIV-infected patients? Clin Exp Immunol 1994; 97(1 Suppl): 59–67
George JN, Woolf SH, Raskob GE. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3–40
Centers for Disease Control and Prevention. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1991; 40(RR-14): 1–10
Barnes GL, Doyle LW, Hewson PH, et al. A randomized trial of oral gammaglobulin in low-birth-weight infants infected with rotavirus. Lancet 1982; 1: 1371–3
Guarino A, Guandalini S, Albano F, et al. Enteral immunoglobulins for treatment of protracted rotaviral diarrhea. Pediatr Infect Dis J 1991; 10: 612–4
Guarino A, Canani RB, Russo S, et al. Oral immunoglobulins for treatment of acute rotaviral gastroenteritis. Pediatrics 1994; 93: 12–6
Yolken R, Kinney J, Wilde J, et al. Immunoglobulins and other modalities for the prevention and treatment of enteric viral infections. J Clin Immunol 1990; 10: 80S–87S
Ebina T, Sato A, Umezu K, et al. Prevention of rotavirus infection by oral administration of cow colostrum containing antihuman rotavirus antibody. Med Microbiol Immunol 1985; 174: 177–85
Davidson GP, Whyte PB, Daniels E, et al. Passive immunisation of children with bovine colostrum containing antibodies to human rotavirus. Lancet 1989; 2: 709–12
Hilpert H, Brussow H, Mietens C, et al. Use of bovine milk concentrate containing antibody to rotavirus to treat rotavirus gastroenteritis in infants. J Infect Dis 1987; 156: 158–66
Mitra AK, Mahalanabis D, Ashraf H, et al. Hyperimmune cow colostrum reduces diarrhoea due to rotavirus: a double-blind, controlled clinical trial. Acta Paediatr 1995; 84: 996–1001
Marwick C. Rotavirus vaccine a boon to children. JAMA 1998; 279: 489–90
Vassilenko SM, Vassilev TL, Bozadjiev LG, et al. Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever [letter]. Lancet 1990; 335: 791–2
Monath TP. Flaviviruses (yellow fever, dengue, dengue hemorrhagic fever, Japanese encephalitis, St. Louis encephalitis, tick-borne encephalitis). In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. N w York: Churchill Livingstone, 1995: 1465–73
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
DesJardin, J.A., Snydman, D.R. Antiviral Immunotherapy. BioDrugs 9, 487–507 (1998). https://doi.org/10.2165/00063030-199809060-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00063030-199809060-00006